8-K: Enzo Biochem to be Acquired by Battery Ventures in $37 Million All-Cash Deal

Enzo Biochem, Inc. has entered into a definitive merger agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction, representing a significant premium to its recent trading price.

Summary

• Enzo Biochem, Inc. (OTCQX: ENZB) entered into an Agreement and Plan of Merger on June 23, 2025, to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures XIV, L.P.
• The acquisition price is $0.70 per share in cash, valuing the company at approximately $37 million.
• This represents a 75% premium to Enzo's closing price on April 22, 2025, following the announcement of the strategic review, and a 32% premium to the closing price on June 23, 2025, the last trading day before the agreement.
• The Company's Board of Directors unanimously approved the merger and resolved to recommend that shareholders vote in favor of the adoption of the Merger Agreement.
• All of the Company's officers and directors, as well as its largest shareholder, have executed support agreements to vote all of their shares in favor of the transaction.
• Each share of common stock issued and outstanding immediately prior to the merger's effective time (excluding certain cancelled or dissenting shares) will be converted into the right to receive $0.70 per share in cash.
• Vested restricted stock units (RSUs) held by board members or vested per their terms will be converted into cash equal to the Merger Consideration.
• All other outstanding unvested RSUs and all options to purchase shares will be canceled without consideration.
• Each warrant to acquire shares will be canceled in exchange for a cash amount set forth in a Warrant Cancellation Agreement.
• The transaction is subject to customary closing conditions, including shareholder approval and a limit on the number of shares exercising statutory dissenters' rights (no more than 10% excluding Wolf Holders).
• The merger is expected to close in the third quarter of the calendar year.
• Following the closing, Enzo Biochem will become a privately held company, and its shares will no longer be listed on public market exchanges.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant premium offered to shareholders, the all-cash nature of the deal, and the unanimous board approval following a comprehensive strategic review aimed at maximizing shareholder value. The transaction provides immediate liquidity and a substantial return for investors.

Positives

• The all-cash offer of $0.70 per share provides immediate and compelling value for shareholders.
• The purchase price represents a significant premium of 75% to the Company's closing price on April 22, 2025, following the announcement of the strategic review.
• It also represents a substantial premium of approximately 32% to the closing price on June 23, 2025, the last trading day before the merger agreement was entered into.
• The Company's Board of Directors unanimously determined that the merger is in the best interests of the Company and its shareholders and approved the transaction.
• All of the Company's officers and directors, along with its largest shareholder, have executed support agreements, indicating strong internal backing for the transaction.

Negatives

• Upon the closing of the transaction, Enzo Biochem, Inc. will become a privately held company, and its shares will be delisted from public market exchanges, removing public trading liquidity.
• Unvested restricted stock units (RSUs) not held by board members and all outstanding stock options will be canceled without any consideration payable to the holders.
• The Company may be required to pay Parent a termination fee of $2.5 million under certain circumstances, such as a change in the Board's recommendation or if an alternative transaction is consummated within 12 months after termination.
• In certain termination scenarios, the Company will be required to reimburse Parent's expenses up to a cap of $1 million.

Risks

• The ability of the Company and Acquirer to complete the Merger on the proposed terms or anticipated timeline, or at all, is subject to risks and uncertainties.
• Securing the necessary approval of the Company's shareholders is a condition to closing.
• Compliance with the covenants contained in the Merger Agreement is required for consummation.
• Satisfaction of other closing conditions to consummate the Merger is necessary.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the Merger.
• Risks related to diverting the attention of the Company's management from ongoing business operations.
• Significant transaction costs and/or unknown or inestimable liabilities are potential risks.
• The risk of shareholder litigation in connection with the Merger, including resulting expense or delay.
• The obligation of Parent to effect the Merger is conditioned upon holders (excluding Wolf Holders) of no more than 10% of outstanding Company Common Stock exercising statutory dissenters' rights.
• The obligation of Parent to effect the Merger is conditioned upon the holders of all Company Warrants having duly executed and delivered a Warrant Cancellation Agreement that remains in full force and effect.
• The occurrence of a 'Company Material Adverse Effect' after the date of the agreement could prevent closing.

Future Outlook

The transaction is anticipated to close in the third quarter of the calendar year, subject to customary closing conditions, including shareholder approval. Following the closing, Enzo Biochem, Inc. will become a privately held company, and its shares will no longer be listed on public market exchanges.

Management Comments

• "This transaction is the outcome of a thorough process to evaluate all potential paths to maximize shareholder value."
• "After careful consideration, the Board unanimously determined that the all-cash offer from Battery delivers immediate and compelling value for our shareholders."

Industry Context

N/A

Management Changes

Corporate Governance

Legal Proceedings

• The document highlights the risk of shareholder litigation in connection with the Merger, including resulting expense or delay.
• The Company is obligated to keep Parent reasonably informed of the status of, and cooperate with Parent in connection with, any shareholder demand, action, or other proceeding related to the Merger.
• The Company will not compromise or settle any Shareholder Litigation without the prior written consent of Parent.

Related Party Transactions

• Concurrently with the execution of the Merger Agreement, all of the Company's officers and directors and the Company's largest shareholder (Harbert Management Corp.) have executed voting and support agreements in favor of Parent and Merger Sub.
• The Parent Funds (Battery Ventures XIV, L.P., Battery Investment Partners XIV, L.P., and Battery Ventures XIV EF, L.P.) have entered into an equity commitment letter with Parent, committing to provide equity financing for the merger.
• The Parent Funds have also entered into a Limited Guaranty in favor of the Company, guaranteeing their pro rata portion of the Parent Termination Fee if it becomes payable under the Merger Agreement.

Stakeholder Impact

• **Shareholders**: Will receive $0.70 per share in cash, providing immediate liquidity and a significant premium over recent trading prices. However, the Company's shares will be delisted from public exchanges, removing future public trading opportunities. Shareholders who do not vote in favor and properly exercise dissenters' rights may be entitled to fair value payment.
• **Employees**: Vested restricted stock units (RSUs) held by board members or vested per their terms will be converted to cash. However, all other unvested RSUs and all outstanding stock options will be canceled without consideration. For continuing employees, Parent will use commercially reasonable efforts to credit years of service for vesting, eligibility, and benefits under new plans.
• **Management**: Current directors will resign at the closing of the merger. The officers of Merger Sub will become the initial officers of the Surviving Corporation. Indemnification and D&O insurance will be maintained for past and present directors and officers for six years.
• **Warrant Holders**: Warrants will be canceled in exchange for a cash amount determined by a Black-Scholes valuation, contingent upon the closing of the Fundamental Transaction.

Next Steps

• The Company will prepare and file a preliminary proxy statement with the SEC within 5 to 10 business days of the Merger Agreement execution.
• The Company will respond promptly to any comments from the SEC or its staff regarding the proxy statement.
• The Company will mail the proxy statement to its shareholders as promptly as reasonably practicable after the resolution of SEC comments.
• The Company will convene and hold a Special Meeting of Shareholders to obtain the Company Shareholder Approval.
• The Company will use reasonable best efforts to obtain all necessary Consents from Governmental Entities and counterparties to Company Material Contracts.
• The Company will cooperate with Parent to cause the removal from trading of the Company Common Stock from the OTCQX and its deregistration under the Exchange Act as promptly as practicable after the Effective Time.
• The Company will deliver resignations executed by each director of the Company in office immediately prior to the Effective Time, effective at the Effective Time.
• The Company will use reasonable best efforts to terminate specific Leases prior to the Closing, provided no fees are required to be paid to landlords for such termination without Parent's consent.
• The merger is expected to close in the third quarter of the calendar year.

Key Dates

Recommendation

Keywords

Enzo Biochem, ENZB, Battery Ventures, Merger Agreement, Acquisition, All-Cash Transaction, Shareholder Value, Strategic Review, Delisting, Biotech, Life Sciences, SEC Filing, 8-K, Corporate Governance, Private Equity